|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial显示文摘AIM: To investigate efficacy and safety of cetuximab combined with two chemotherapy regimens in patients with unresectable metastatic colorectal cancer (mCRC). METHODS: Randomized patients received cetuximab with 5-fluorouracil (5-FU), folinic acid (FA) and oxaliplatin (FOLFOX) 6 (arm A, n = 74) or 5-FU, FA and irinotecan (FOLFIRI) (arm B, n = 77). KRAS mutation status was determined retrospectively in a subset of tumors (n = 117). RESULTS: No significant difference was found between treatment arms A and B in the progression-free survival (PFS) rate at 9 mo, 45% vs 34%; median PFS, 8.6 mo vs 8.3 mo [hazard ratio (HR) = 1.06]; overall response rate (ORR) 43% vs 45% [odds ratio (OR) = 0.93] and median overall survival (OS), 17.4 mo vs 18.9 mo (HR = 0.98). Patients with KRAS wild-type tumors demonstrated improved PFS (HR = 0.55, P = 0.0051), OS, (HR = 0.62, P = 0.0296) and ORR (53% vs 36%) and in arm A, improved PFS (HR = 0.49, P = 0.0196), OS (HR = 0.48, P = 0.0201) and ORR (56%vs 30%), compared with patients with KRAS mutated tumors. In arm B no significant differences were found in efficacy by KRAS mutation status. Treatment in arms A and B was generally well tolerated. CONCLUSION: This study confirms that combinations of cetuximab with FOLFOX6 or FOLFIRI are effective and significantly improve clinical outcome in KRAS wild-type compared with KRAS mutated mCRC. | Janja Ocvirk Thomas Brodowicz Fritz Wrba Tudor E Ciuleanu Galina Kurteva Semir Beslija Ivan Koza Zsuzsanna Pápai Diethelm Messinger Ugur Yilmaz Zsolt Faluhelyi Suayib Yalcin Demetris Papamichael Miklós Wenczl Zrinka Mrsic-Krmpotic Einat Shacham-Shmueli Damir Vrbanec Regina Esser Werner Scheithauer Christoph C Zie-linski | 2010 | World Journal of Gastroenterology2010，16，25： | 17 |
| 2 | Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer显示文摘 | Giorgio Scagliotti Thomas Brodowicz Frances A. Shepherd Christoph Zielinski Johan Vansteenkiste Christian Manegold Lorinda Simms Frank Fossella Katherine Sugarman Chandra P. Belani | 2011 | Journal of Thoracic Oncology2011，，1： | 2 |
| 3 | Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab‐based treatment response in metastatic colorectal cancer显示文摘 | Gerald W. Prager Kira H. Braemswig Alexandra Martel Matthias Unseld Georg Heinze Thomas Brodowicz Werner Scheithauer Gabriela Kornek Christoph C. Zielinski | 2014 | Cancer Sci2014，，8： | 2 |
| 4 | Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer:a randomised,double-blind,phase 3 study显示文摘 | Ciuleanu T Brodowicz T Zielinski C | | 0，，： | 1 |
| 5 | Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study显示文摘 | Ciuleanu T Brodowicz T Zielinski C | 2009 | Lancet2009，374，： | 1 |
| 6 | Monotherapy with docetaxel in second - or third - line treatment of anthracycline - resistant metastatic breast cancer显示文摘 | Brodowicz T Koestler WJ Tomek S | 2000 | Anticancer Drugs2000，11，3： | 1 |
| 7 | Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non small-cell lung cancer:A randomised, double-blind, phase 3 study显示文摘 | Ciuleanu T Brodowicz T Zielinski C | 2009 | Lancet2009，374，9： | 1 |
| 8 | Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer:a randomized,double-blind,phase 3 study显示文摘 | Ciuleanu T Brodowicz T Zielinski C | 2009 | Lancet2009，374，9699： | 1 |
| 9 | Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer:a randomised,double-blind,phase 3 study显示文摘 | Ciuleanu T Brodowicz T Zielinski C | | 0，，9699： | 1 |
| 10 | Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase Ⅲ trial显示文摘 | Brodowicz T Krzakowski M Zwitter M | 2006 | Lung Cancer2006，52，2： | 1 |
| 11 | Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase Ⅲ study显示文摘 | Ciuleanu TE Brodowicz T Belani CP | 2008 | J Clin Oneol2008，，： | 1 |
| 12 | Maintenance pemetrexed plus best supportive care (BSC)versus placebo plus BSC: A phase Ⅲ study显示文摘 | Cluleanu TE Brodowicz T Belani CP | 2008 | J Clin Oncol2008，26，1： | 1 |
| 13 | Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised: double-blind,phase 3 study显示文摘 | Ciuleanu T Brodowicz T Zielinski C | 2009 | Lancet2009，374，9699： | 1 |
| 14 | Maintenan- cepeme-trexed plus bestsupportive care (BSC) versus placebo plusBSC:A phase study显示文摘 | Ciuleanu TE Brodowicz T Belani CP | 2008 | J Clin Oncol2008，26，15： | 1 |
| 15 | Monotherapy with docetaxel in second or third- line treatment of anthracycline risistant metastatic breast cancer显示文摘 | Brodowicz T Kosetler W J | 2000 | Anticancer Drugs2000，11，3： | 1 |
| 16 | Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer 显示文摘 | Scagliotti G Brodowicz T Shepherd FA | 2011 | J Tho- rac Oncol2011，6，1： | 1 |
| 17 | Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro显示文摘 | Brodowicz T Wiltschke C Budinsky A C | 1997 | Int J Cancer1997，73，6： | 1 |
| 18 | Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer:a randomised,double-blind,phase 3 study显示文摘 | Ciuleanu T Brodowicz T Zielinski C | | 0，，： | 1 |
| 19 | Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer:A phase Ⅲ trial显示文摘 | Brodowicz T Krzakowski M Zwitter M | | 0，，02： | 1 |
| 20 | Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer:a phaseⅢtrial显示文摘 | Brodowicz T Krzakowski M Zwitter M | | 0，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员